Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:45 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 5,921 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mouth Disease Clear all
Completed Phase 2 Interventional Results available

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

NCT00721409
View directory record Official record
Conditions
Breast Cancer
Interventions
PD 0332991, letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
51
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 3 Interventional Results available

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT06045221
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Orforglipron, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
64
States / cities
Phoenix, Arizona • Canoga Park, California • Escondido, California + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

NCT03578367
View directory record Official record
Conditions
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
Interventions
Asciminib add-on, Imatinib, Nilotinib, Asciminib 80mg QD (asciminib single agent (ASAC))
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Augusta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 2 Interventional

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

NCT00746967
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological, Sexual Arousal Disorder
Interventions
sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
82
States / cities
Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 3 Interventional Results available

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

NCT02268214
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo for dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Little Rock, Arkansas • Encino, California • La Mesa, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Nov 1, 2026, 4:45 AM EST
Completed No phase listed Observational

Role of IL-37 Genetic Variants in Modulating Innate Immune Response to Periodontal Pathogens

NCT03161301
View directory record Official record
Conditions
Periodontal Diseases
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 3 Interventional Results available

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

NCT00056407
View directory record Official record
Conditions
Neoplasms, Prostate
Interventions
Dutasteride, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years · Male only
Enrollment
8,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
297
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 236 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Nov 1, 2026, 4:45 AM EST
Not listed Phase 3 Interventional

PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke

NCT02541032
View directory record Official record
Conditions
Periodontal Disease, Stroke, TIA
Interventions
Intensive dental treatment, Standard dental treatment, Arestin
Procedure · Drug
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

NCT05686980
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-552
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Anaheim, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Nov 1, 2026, 4:45 AM EST
Withdrawn No phase listed Observational

Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation

NCT01607359
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 1 Interventional

BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer

NCT01339442
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
BKM120, Fulvestrant, biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Nov 1, 2026, 4:45 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

LT Comparative Effectiveness of 2 Caries Treatments

NCT07213661
View directory record Official record
Conditions
Dental Caries
Interventions
A "simple medical strategy" consisting of silver diamine fluoride (SDF), A "typical dental strategy" consisting of atraumatic restorative treatment (ART) with glass ionomer cement + Fluoride Varnish (FV)
Device
Lead sponsor
Case Western Reserve University
Other
Eligibility
62 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 2 Interventional

Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure

NCT00132886
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
26
States / cities
Huntsville, Alabama • Merced, California • Sylmar, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Nov 1, 2026, 4:45 AM EST
Terminated Phase 4 Interventional Results available

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

NCT02117050
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 3 Interventional

Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

NCT00137462
View directory record Official record
Conditions
Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
48
States / cities
Huntsville, Alabama • Union Grove, Alabama • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2007 · Synced Nov 1, 2026, 4:45 AM EST
Not yet recruiting Phase 1Phase 2 Interventional

A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

NCT07053020
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Cytarabine, Oral Cladribine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

NCT05630846
View directory record Official record
Conditions
Measles; Mumps; Rubella; Chickenpox, Measles
Interventions
Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine, Marketed MMRV_Lot 1 and Lot 2 vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Bellflower, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Nov 1, 2026, 4:45 AM EST
Recruiting Phase 2 Interventional

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

NCT07745361
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Interventions
Oral MRT-2359, Apalutamide
Drug
Lead sponsor
Monte Rosa Therapeutics, Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Colorado Springs, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 1, 2026, 4:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Colorado Oral Strengthening Device

NCT05464225
View directory record Official record
Conditions
Parkinson Disease
Interventions
COSD, SOC
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Nov 1, 2026, 4:45 AM EST
Completed Not applicable Interventional

Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes

NCT01932476
View directory record Official record
Conditions
Type 1 Diabetes, Celiac Disease
Interventions
Gluten Challenge, Sham Challenge
Dietary Supplement
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 2 Interventional Results available

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

NCT03462459
View directory record Official record
Conditions
Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI, C.Difficile Diarrhea, C. Diff Colitis, C.Difficile Colitis
Interventions
Vancomycin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Nov 1, 2026, 4:45 AM EST
Recruiting Phase 4 Interventional

Systemic Oral Glucocorticoids for the Treatment of Acute Osteoarthritis Pain in the Emergency Department

NCT06603662
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Shoulder, Osteoarthritis (OA) of the Hip
Interventions
Prednisone, Dexamethasone, Placebo
Drug
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 1, 2026, 4:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Zinc Supplementation in Alcoholic Cirrhosis

NCT02072746
View directory record Official record
Conditions
Alcoholic Cirrhosis
Interventions
Zinc, Placebo
Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Nov 1, 2026, 4:45 AM EST
Recruiting Not applicable Interventional

Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.

NCT07187388
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Nov 1, 2026, 4:45 AM EST